Company Overview
RECURSION PHARMACEUTICALS, INC.
RXRXRevenue vs. Cost of Revenue
Revenue
Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses
Operating Income
Net Income
Net Income
Revenue
75M
2025 FY
Net Income
-645M
2025 FY
Shares Outstanding
447M
2025 FY
EPS
-1.44USD
2025 FY
Company Information
SIC Code
2836
CIK Code
1601830
Exchange
Nasdaq
Location
US